[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342524-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342524-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-review-on-trends-in-development-and-translation-of-omics-signatures-in-cancer","A review on trends in development and translation of omics signatures in cancer","","The field of cancer genomics and transcriptomics has advanced from targeted profiling to rapid sequencing of individual tumor genome and transcriptome. Expanding genome, epigenome, and transcriptome datasets enable signature capture that encodes both intrinsic and extrinsic tumor features, supporting molecular subtyping, progression and metastatic prediction, and therapy resistance assessment. This review consolidates developments of genomic, methylomic, transcriptomic, proteomic, and metabolic signatures and emphasizes their clinical potential for improving cancer diagnosis, prognosis, and treatment decisions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-review-on-trends-in-development-and-translation-of-omics-signatures-in-cancer/342524/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-review-on-trends-in-development-and-translation-of-omics-signatures-in-cancer/342524.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How have omics signatures in cancer research evolved according to the review?","Question",{"text":63,"@type":64},"The review describes a shift from targeted profiling to fast sequencing of individual tumor genome and transcriptome, enabled by continuing growth of genome, epigenome, and transcriptome datasets.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What can mutational signatures help reveal about tumors?",{"text":68,"@type":64},"Mutational signatures reflect endogenous and exogenous mutational processes and can indicate defects in DNA-repair pathways, supporting insights into tumor etiology and enabling advances in early detection and therapeutic implications.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical applications of omics signatures are highlighted?",{"text":72,"@type":64},"The review highlights their potential to improve molecular subtyping, predict tumor progression and metastatic potential, and inform treatment decision-making, including therapy resistance assessment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342524,1790172737,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Computational and Structural Biotechnology Journal 23 (2024) 954–971  \nContents lists available at ScienceDirect  \nComputational and Structural Biotechnology Journal  \njournal [homepage:](homepage: www.elsevier.com/locate/csbj)[ www.elsevier.com/locate/csbj](homepage: www.elsevier.com/locate/csbj)  \n| Mini-review\u003Cbr>A review on trends in development and translation of omics signatures in cancer |  |  | |\n| --- | --- | --- | --- |\n| Wei Maa, 1, Wenshu Tanga, 1, Jamie S.L. Kwok a, Amy H.Y. Tonga, Cario W.S. Loa, Annie T.W. Chua, Brian H.Y. Chung a, b, *, Hong Kong Genome Project\u003Cbr>a Hong Kong Genome Institute, Hong Kong, China\u003Cbr>b Department of Pediatrics and Adolescent Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>Cancer genomics\u003Cbr>Transcriptomics\u003Cbr>DNA methylation\u003Cbr>Mutational signatures\u003Cbr>Machine learning\u003Cbr>Translational Medicine |  | The field of cancer genomics and transcriptomics has evolved from targeted profiling to swift sequencing of individual tumor genome and transcriptome. The steady growth in genome, epigenome, and transcriptome datasets on a genome-wide scale has significantly increased our capability in capturing signatures that represent both the intrinsic and extrinsic biological features of tumors. These biological differences can help in precise molecular subtyping of cancer, predicting tumor progression, metastatic potential, and resistance to therapeutic agents. In this review, we summarized the current development of genomic, methylomic, transcriptomic, proteomic and metabolic signatures in the field of cancer research and highlighted their potentials in clinical applications to improve diagnosis, prognosis, and treatment decision in cancer patients. |  |\n\n1. Introduction  \nWith the advance in sequencing technologies, whole-genome and whole-transcriptome sequencing have now been widely used in cancer studies to provide researchers with information of DNA mutation, DNA methylation and gene expression at a genome-wide level. Together with the advances in mass spectrometry which enabled in depth analysis of proteomic and metabolic profiles in cancers, the omics signatures have been studied for their use in different clinical applications in cancer patients (Fig. 1). It has been shown that by discerning generic patterns in genomic data, one can reveal the basic biological properties of a tumor such as defects in DNA-repair pathways [1]. For example, consistent patterns of DNA mutagenesis across breast tumours can be used to identify BRCA1-null and BRCA2-null tumors [2]. In some cases, one can even distinguish tumors showing impairment in the BRCA-pathway but without having apparent mutations in the BRCA1/2 genes themselves, which enables identification of patients who will respond better to PARP inhibitors [3]. This lifts off the limitation of our knowledge of biology from preventing clinical translation of genomic and transcriptomic results. This is, in part, due to the fact that genome-wide signature analysis of DNA mutation, DNA methylation and gene expression can reveal not only the effect of tumor cell intrinsic pathways but also the interaction  \nbetween tumor cells and the microenvironment [4–6]. Moreover, development of new mathematical and computational tool is essential in improving the understanding of the complex genome-wide sequencing data and extracting abstract patterns which are associated with specific biological and/or clinical features of the tumor [7–9].  \n2. DNA mutational signature in cancer  \nMutations accumulate with age and multiple exposures, engraving characteristic mutational patterns or imprints in the genome of somatic cells, termed as mutational signatures. Mutational signatures represent genome-wide somatic alteration patterns and reflect the activities of endogenous and exogenous mutational processes. For example, DNA repair deficien","cbCaie9zsGzT6Gb1","https://ap.wps.com/l/cbCaie9zsGzT6Gb1","pdf",4487025,18,"English","# Introduction\n## DNA mutational signature in cancer\n### Detecting SNV mutational signatures","[{\"question\":\"How have omics signatures in cancer research evolved according to the review?\",\"answer\":\"The review describes a shift from targeted profiling to fast sequencing of individual tumor genome and transcriptome, enabled by continuing growth of genome, epigenome, and transcriptome datasets.\"},{\"question\":\"What can mutational signatures help reveal about tumors?\",\"answer\":\"Mutational signatures reflect endogenous and exogenous mutational processes and can indicate defects in DNA-repair pathways, supporting insights into tumor etiology and enabling advances in early detection and therapeutic implications.\"},{\"question\":\"What clinical applications of omics signatures are highlighted?\",\"answer\":\"The review highlights their potential to improve molecular subtyping, predict tumor progression and metastatic potential, and inform treatment decision-making, including therapy resistance assessment.\"}]","A review on trends in development and translation of omics signatures in cancer | PDF",1790046982,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8d45a5ee0ee1cba41edafa6c9729101.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55802c7ec9f6774526e1ad86cc8b2937.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/faf4590fd65db0280ab47c54cc048e41.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb06a412cfe8da9ccfa6e5af55709f5f.webp",980,1306]